Trial Profile
An Open Label, Parallel-Arm, Multicenter Trial Assessing the Acceptability of 4 Dosages of a New Fixed Dose Combination of Fenofibrate and Metformin in Patients With Type 2 Diabetes and Dyslipidemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Apr 2010
Price :
$35
*
At a glance
- Drugs Fenofibrate/metformin (Primary)
- Indications Dyslipidaemias; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Abbott Laboratories; Fournier Laboratories Ireland
- 29 Oct 2006 New trial record.